Loading...
Cardiol Therapeutics Inc.
CRDL.TO•TSX
Healthcare
Drug Manufacturers - Specialty & Generic
CA$1.91
CA$-0.15(-7.28%)
Cardiol Therapeutics Inc. (CRDL.TO) Financial Performance & Income Statement Overview
Review Cardiol Therapeutics Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
0.00%
Operating Income Growth
-35.22%
↓ 35.22%
Net Income Growth
-30.39%
↓ 30.39%
Operating Cash Flow Growth
-99425.13%
↓ 99425.13%
Operating Margin
0.00%
Gross Margin
0.00%
Net Profit Margin
0.00%
ROE
-210.17%
↓ 210.17%
ROIC
-147.76%
↓ 147.76%
Cardiol Therapeutics Inc. (CRDL.TO) Income Statement & Financial Overview
Review Cardiol Therapeutics Inc.'s (CRDL.TO) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $61908.00 | $61623.00 |
| Gross Profit | $0.00 | $0.00 | -$61908.00 | -$61623.00 |
| Gross Profit Ratio | ||||
| R&D Expenses | $4.23M | $3.75M | $2.71M | $3.32M |
| SG&A Expenses | $5.76M | $10.39M | $4.97M | $5.02M |
| Operating Expenses | $9.99M | $14.14M | $7.68M | $8.34M |
| Total Costs & Expenses | $9.99M | $14.14M | $7.74M | $8.41M |
| Interest Income | $306775.00 | $201864.00 | $307409.00 | $377294.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $48493.00 | $201090.00 | $61908.00 | $61623.00 |
| EBITDA | -$9.94M | -$13.94M | -$7.68M | -$8.36M |
| EBITDA Ratio | ||||
| Operating Income | -$9.99M | $0.00 | -$7.74M | -$8.41M |
| Operating Income Ratio | ||||
| Other Income/Expenses (Net) | $1.81M | -$12.73M | $1.15M | -$774151.00 |
| Income Before Tax | -$8.18M | -$12.73M | -$6.59M | -$9.18M |
| Income Before Tax Ratio | ||||
| Income Tax Expense | $0.00 | $0.00 | $0.00 | -$2.00 |
| Net Income | -$8.18M | -$12.73M | -$6.59M | -$9.18M |
| Net Income Ratio | ||||
| EPS | -$0.12 | -$0.18 | -$0.10 | -$0.14 |
| Diluted EPS | -$0.12 | -$0.18 | -$0.10 | -$0.14 |
| Weighted Avg Shares Outstanding | $81.78M | $69.84M | $68.75M | $67.26M |
| Weighted Avg Shares Outstanding (Diluted) | $81.78M | $69.84M | $68.75M | $67.26M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan